Every material Form 8-K Edgewell Personal Care filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Edgewell Personal Care said LaTanya Langley will become Chief Administrative and Legal Officer and Corporate Secretary effective October 1, 2026, and will leave her Chief People Officer role on the same date. The filing states there are no changes to her compensation tied to these role changes.
Role change effective October 1, 2026, determined by the company on September 17, 2026
Langley will no longer serve as Chief People Officer as of October 1, 2026
No change to Langley's compensation in connection with the role changes
Edgewell reported fiscal third-quarter 2026 results for the quarter ended June 30, 2026. Net sales rose 1.7% to $570.1 million and adjusted EPS was flat at $0.72, while GAAP diluted EPS fell to $0.26 from $0.46. The company narrowed its full-year adjusted EPS range to $1.80 to $2.00 with the midpoint unchanged, but lowered its GAAP EPS outlook to flat to $0.20 and raised its expected restructuring-related charges to about $92 million.
Third-quarter net sales were $570.1 million, up 1.7%; organic net sales rose 1.1%, with North America up 3.0% and International down 1.4%.
Adjusted EPS was $0.72, unchanged from the prior year; GAAP diluted EPS was $0.26 versus $0.46.
Full-year adjusted EPS outlook narrowed to $1.80 to $2.00 from $1.70 to $2.10; GAAP EPS outlook lowered to flat to $0.20 from flat to $0.40.
The Board declared a quarterly dividend of $0.15 per share, payable October 8, 2026 to holders of record on September 9, 2026.
Edgewell Personal Care said Paul R. Hibbert will leave his role as Chief Supply Chain Officer effective June 1, 2026, and that Anthony Freve will succeed him in that role on the same date. The filing does not describe the reasons for the change, and the company is not reporting financial figures in this filing.
Paul R. Hibbert will no longer serve as Chief Supply Chain Officer, effective June 1, 2026; the company made this determination on May 20, 2026.
Hibbert is eligible for payments and benefits under the Company's Executive Severance Plan.
Anthony Freve will join Edgewell as Chief Supply Chain Officer, effective June 1, 2026, according to an announcement on May 26, 2026.
Edgewell reported fiscal second-quarter 2026 results, excluding the divested Feminine Care business. Net sales rose 0.6% to $519.5 million, but organic net sales fell 2.4% and adjusted EPS declined to $0.60 from $0.69. The company cut its full-year GAAP EPS outlook to flat to $0.40 from $0.55 to $0.95 because of higher restructuring and legal costs, while keeping its adjusted EPS outlook at $1.70 to $2.10.
Q2 net sales $519.5 million, up 0.6%; organic net sales down 2.4%
GAAP diluted EPS $0.09 vs. $0.43 a year earlier; adjusted EPS $0.60 vs. $0.69
FY2026 GAAP EPS outlook lowered to flat to $0.40; expected restructuring charges raised to about $90 million from $65 million
Quarterly dividend of $0.15 per share declared, payable July 9, 2026 to holders of record June 10, 2026
Edgewell reported first-quarter fiscal 2026 results with continuing-operations net sales of $422.8 million, up 1.9%, but a wider loss of $0.63 per diluted share from continuing operations versus $0.21 a year earlier. The company also completed the sale of its Feminine Care business for $340 million and now reports its outlook on a continuing-operations basis, which shows lower adjusted EPS and EBITDA ranges than the prior consolidated outlook because Feminine Care is removed.
Continuing-operations net sales were $422.8 million, up 1.9%; organic net sales decreased 0.5%.
Adjusted EPS was $(0.16) versus $(0.10) a year earlier; GAAP loss per diluted share was $(0.63) from continuing operations and $(1.41) including discontinued operations.
Fiscal 2026 adjusted EPS outlook is $1.70 to $2.10 on a continuing basis, versus $2.15 to $2.55 previously; the company says the full-year outlook for continuing operations is unchanged from its prior outlook.
Expected pre-tax restructuring and related charges for fiscal 2026 rose to approximately $65 million from $49 million.
Edgewell Personal Care closed the sale of its Feminine Care segment to Essity on February 2, 2026, receiving approximately $340 million in cash, subject to post-closing adjustments. The company plans to use the net proceeds mainly to pay down its U.S. revolving credit facility, and its pro forma filing estimates a loss on disposal and goodwill impairment of $42.1 million net of tax, which the company says may differ materially from the final figure.
Closing date was February 2, 2026; the company received about $340 million in cash from Essity, subject to adjustments for inventory, indebtedness and other items.
Pro forma filing shows $140.0 million outstanding on the revolving credit facility as of September 30, 2025, assumed to be repaid with sale proceeds.
Estimated loss on disposal and goodwill impairment of $42.1 million, net of tax, based on September 30, 2025 balances; the goodwill impairment alone was $37.4 million.
Transition services agreement with Essity covers accounting, IT, quality assurance, operations, supply chain and sales for at least one year.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Edgewell Personal Care filing is on SEC EDGAR ↗. 8-K briefs of other companies →